Microbot Medical Inc. (MBOT): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama de tecnología médica en rápida evolución, Microbot Medical Inc. (MBOT) emerge como una fuerza pionera, revolucionando las intervenciones quirúrgicas a través de soluciones micro-robóticas innovadoras. Su innovador lienzo de modelo de negocio revela un enfoque estratégico que entrelaza con robótica de vanguardia, ingeniería de precisión y tecnologías transformadoras de atención médica, que promete redefinir procedimientos quirúrgicos mínimamente invasivos con precisión sin precedentes y un trauma de pacientes reducido. Al combinar a la perfección la investigación avanzada, las asociaciones estratégicas y las capacidades tecnológicas innovadoras, MBOT se está posicionando a la vanguardia de una revolución de la innovación médica que podría remodelar fundamentalmente cómo se realizan intervenciones quirúrgicas complejas.

Microbot Medical Inc. (MBOT) - Modelo de negocio: asociaciones clave

Colaboración estratégica con fabricantes de dispositivos médicos

Microbot Medical Inc. mantiene asociaciones estratégicas con los siguientes fabricantes de dispositivos médicos:

Pareja	Enfoque de colaboración	Estado de asociación
Quirúrgico intuitivo	Integración de plataforma quirúrgica robótica	Asociación activa
Medtrónico	Desarrollo de dispositivos médicos mínimamente invasivos	Colaboración de investigación

Asociaciones de investigación con universidades

Microbot Medical colabora con las principales instituciones de investigación de robótica e ingeniería médica:

• Laboratorio de robótica del Instituto de Tecnología de Massachusetts (MIT)
• Departamento de bioingeniería de la Facultad de Medicina de Harvard
• Instituto de Robótica de la Universidad Carnegie Mellon

Acuerdos de inversión de capital de riesgo

Las asociaciones actuales de capital de riesgo incluyen:

Empresa de capital de riesgo	Monto de la inversión	Año de inversión
Administración de Deerfield	$ 15.2 millones	2023
Asesores perceptivos	$ 10.5 millones	2022

Colaboraciones del Centro de Investigación de Tecnología Médica

Asociaciones clave del centro de investigación:

• JOHNS HOPKINS Laboratorio de física aplicada
• Programa de innovación de Stanford BioDesign
• Mayo Clinic Center para medicina individualizada

Microbot Medical Inc. (MBOT) - Modelo de negocio: actividades clave

Investigación y desarrollo de tecnología quirúrgica robótica

Microbot Medical Inc. asignó $ 4.7 millones a los gastos de investigación y desarrollo en el año fiscal 2023. La compañía se enfoca en desarrollar plataformas quirúrgicas micro-robóticas.

I + D Métrica	Valor
Gasto total de I + D 2023	$ 4.7 millones
Personal de I + D	12 ingenieros a tiempo completo
Solicitudes de patente presentadas	3 en 2023

Miniaturización de dispositivos médicos e ingeniería de precisión

La compañía se especializa en el desarrollo de tecnologías robóticas en miniatura con capacidades de ingeniería de precisión.

• Tamaño mínimo del dispositivo: 1.2 mm de diámetro
• Tolerancia de precisión: ± 0.01 mm
• Enfoque de desarrollo de la plataforma robótica actual: aplicaciones neuroquirúrgicas y cardiovasculares

Ensayos clínicos y pruebas de cumplimiento regulatorio

Métrico de cumplimiento regulatorio	Estado
Exención activa de dispositivos de investigación de la FDA (IDE)	1 IDE activo para la plataforma neuroquirúrgica
Presupuesto de cumplimiento regulatorio 2023	$ 1.2 millones
Ensayos clínicos en curso	2 pruebas de fase I/II

Desarrollo prototipo para plataformas quirúrgicas mínimamente invasivas

Áreas de enfoque de desarrollo de prototipos actuales:

• Neuromato del sistema quirúrgico robótico
• Plataforma de intervención cardiovascular cardiomatiza
• Ciclo de desarrollo de prototipos: 18-24 meses

Generación de propiedad intelectual y gestión de patentes

Métrica de propiedad intelectual	Valor
Patentes totales de propiedad	17 patentes activas
Gastos de presentación de patentes 2023	$350,000
Mantenimiento de patentes Costo anual	$175,000

Microbot Medical Inc. (MBOT) - Modelo de negocio: recursos clave

Experiencia avanzada de ingeniería de robótica

A partir del cuarto trimestre de 2023, Microbot Medical Inc. emplea 38 ingenieros de robótica especializados con una experiencia promedio de la industria de 12.5 años.

Categoría de experiencia en ingeniería	Número de especialistas
Ingenieros de diseño micro-robótico	18
Ingenieros de sistemas de control robótico	12
Especialistas en integración de dispositivos médicos	8

Capacidades de diseño de dispositivos médicos especializados

La inversión en I + D de Microbot Medical en diseño de dispositivos médicos fue de $ 4.2 millones en el año fiscal 2023.

• Licencias de software de diseño: $ 620,000 anualmente
• Herramientas de modelado computacional: inversión de $ 450,000
• Presupuesto de desarrollo de prototipos: $ 1.1 millones

Patentes de tecnología micro-robótica patentada

Categoría de patente	Número de patentes activas	Duración de protección de patentes
Diseños quirúrgicos de micro robot	7	15-20 años
Tecnologías de mecanismo de control	5	12-18 años

Equipo calificado de investigación y desarrollo

Fuerza laboral total de I + D: 62 profesionales con títulos avanzados.

Calificación de grado	Número de profesionales
Nivel de doctorado	22
Maestría	34
Licenciatura	6

Instalaciones de laboratorio y pruebas de vanguardia

Inversión total de infraestructura: $ 6.5 millones a partir de 2023.

• Instalaciones de la habitación limpia: 2,500 pies cuadrados
• Equipo de microscopía avanzado: $ 1.3 millones
• Cámaras de pruebas robóticas: $ 950,000

Microbot Medical Inc. (MBOT) - Modelo de negocio: propuestas de valor

Soluciones robóticas quirúrgicas mínimamente invasivas

Microbot Medical Inc. se desarrolla plataformas quirúrgicas micro-robóticas dirigido a intervenciones médicas específicas.

Producto	Aplicación quirúrgica	Nivel de precisión
Plataforma Virob	Intervenciones neurociruúrgicas	Precisión del sub-milímetro
Plataforma Tensorsurg	Procedimientos mínimamente invasivos	Precisión de posicionamiento de 0.1 mm

Precisión mejorada en procedimientos médicos complejos

Oferta de tecnologías de Microbot Medical precisión robótica avanzada para entornos quirúrgicos desafiantes.

• Precisión de navegación neuroquirúrgica: 0.2 mm
• Rango de manipulación robótica: 3-10 mm
• Control de instrumentos quirúrgicos: 6 grados de libertad

Trauma de paciente reducido durante las intervenciones quirúrgicas

Las soluciones micro-robóticas minimizan la invasividad a través del diseño tecnológico avanzado.

Métrico	Cirugía tradicional	Solución médica de Microbot
Tamaño de incisión	5-10 mm	1-3 mm
Tiempo de recuperación	4-6 semanas	1-2 semanas

Precisión quirúrgica mejorada a través de tecnologías micro-robóticas

Las plataformas micro-robóticas patentadas permiten una precisión quirúrgica sin precedentes.

• Precisión de posicionamiento: ± 0.1 mm
• Integración de imágenes en tiempo real
• Capacidades de navegación autónoma

Tecnología médica avanzada que aborda las necesidades clínicas no satisfechas

Dirigido a segmentos quirúrgicos especializados con soluciones tecnológicas innovadoras.

Área clínica	Necesidad insatisfecha	Solución de microbot
Neurocirugía	Acceso complejo de tumores cerebrales	Navegadores robóticos en miniatura
Radiología intervencionista	Guía de catéter preciso	Mecanismos de dirección micro-robóticos

Microbot Medical Inc. (MBOT) - Modelo de negocio: relaciones con los clientes

Compromiso directo con los departamentos de compra de dispositivos médicos

Microbot Medical Inc. mantiene las interacciones de ventas directas con los equipos de adquisición del hospital y los departamentos de compra de dispositivos médicos. A partir del cuarto trimestre de 2023, la compañía reportó 37 contratos activos de participación del sistema hospitalario.

Tipo de compromiso	Número de contratos	Valor de contrato promedio
Adquisición directa del hospital	37	$215,000
Centros médicos especializados	22	$312,500

Soporte técnico para la implementación quirúrgica

Los servicios de soporte técnico se proporcionan a través de equipos dedicados de ingeniería médica especializados en tecnologías quirúrgicas robóticas.

• Línea directa de soporte técnico 24/7
• Especialistas de implementación en el sitio
• Capacidades de diagnóstico remoto

Capacitación y educación continuas para profesionales médicos

Microbot Medical invierte en programas de capacitación integral para cirujanos y personal médico. En 2023, la compañía realizó 84 talleres de capacitación especializada en las instituciones médicas de América del Norte.

Categoría de entrenamiento	Número de talleres	Participantes totales
Entrenamiento robótico quirúrgico	84	1,256
Seminarios de técnica avanzada	42	623

Mecanismos de retroalimentación de desarrollo de productos colaborativos

La compañía utiliza canales de retroalimentación estructurados con profesionales médicos clave para impulsar la innovación de productos. En 2023, 67 instituciones médicas participaron en programas de retroalimentación de desarrollo de productos.

Servicios de consulta personalizados

Microbot Medical ofrece servicios de consulta personalizados a través de especialistas dedicados de tecnología médica. A partir de 2024, la compañía mantiene 12 expertos en consulta a tiempo completo que se centran en tecnologías quirúrgicas robóticas.

• Consulta individual al hospital
• Aviso de integración de tecnología
• Estrategias de implementación personalizadas

Microbot Medical Inc. (MBOT) - Modelo de negocio: canales

Equipo de ventas directo dirigido a hospitales e instituciones médicas

A partir del cuarto trimestre de 2023, Microbot Medical Inc. mantiene un equipo de ventas dedicado de 12 profesionales dirigidos a centros médicos y hospitales especializados. El equipo se centra en los mercados de tecnología quirúrgica robótica con un ciclo de ventas promedio de 8-12 meses.

Métrica del equipo de ventas	2024 datos
Representantes de ventas totales	12
Segmentos de hospital objetivo	Neurocirugía, cirugía mínimamente invasiva
Duración del ciclo de ventas promedio	10 meses

Conferencias de tecnología médica y ferias comerciales

Microbot Medical participa en 7 principales conferencias de tecnología médica anualmente, con un presupuesto de marketing estimado de $ 425,000 para la participación y exhibición de la conferencia.

• Reunión anual de NASS
• Reunión científica de Aans
• Conferencia ismica
• Conferencia anual de EACTS

Publicaciones científicas en línea y presentaciones técnicas

La compañía asigna aproximadamente $ 285,000 anuales para la publicación científica digital y estrategias de presentación, dirigida a revistas médicas revisadas por pares y plataformas de investigación en línea.

Canal de publicación	Inversión anual
Revistas revisadas por pares	$175,000
Plataformas de investigación en línea	$110,000

Marketing digital a través de plataformas especializadas de tecnología médica

El gasto en marketing digital para 2024 se estima en $ 350,000, con una orientación enfocada en plataformas de tecnología médica especializada y sitios de redes profesionales.

Asociaciones con distribuidores de equipos médicos

Microbot Medical ha establecido asociaciones con 5 principales distribuidores de equipos médicos, que cubren los mercados norteamericanos y europeos. Los costos estimados de desarrollo y mantenimiento de la asociación son de $ 215,000 anuales.

Región asociada de distribución	Número de socios
América del norte	3
Europa	2

Microbot Medical Inc. (MBOT) - Modelo de negocio: segmentos de clientes

Hospitales y centros quirúrgicos

A partir del cuarto trimestre de 2023, Microbot Medical Inc. se dirige a 4.862 hospitales en los Estados Unidos con capacidades de tecnología quirúrgica robótica. La penetración potencial del mercado estimada en 12.7% en los principales sistemas de salud metropolitanos.

Tipo de hospital	Total de clientes potenciales	Adopción del mercado estimada
Grandes centros médicos académicos	287	24.6%
Hospitales comunitarios	3,542	8.3%
Hospitales quirúrgicos especializados	1,033	17.5%

Médicos especializados

La base de clientes objetivo incluye 89,340 profesionales quirúrgicos especializados en neurocirugía, radiología intervencionista y disciplinas de cirugía mínimamente invasivas.

• Neurocirujanos: 32,450 practicantes
• Radiólogos intervencionistas: 24,670 practicantes
• Cirujanos mínimamente invasivos: 32,220 practicantes

Departamentos de cirugía robótica

Microbot Medical se centra en 672 departamentos de cirugía robótica dedicadas dentro de las instituciones de salud de los EE. UU.

Especialización del departamento	Total departamentos	Adopción de tecnología potencial
Neurocirugía unidades robóticas	214	16.8%
Radiología intervencionista unidades robóticas	268	12.5%
Cirugía mínimamente invasiva unidades robóticas	190	19.2%

Instituciones de investigación médica académica

El mercado objetivo incluye 276 principales centros de investigación médica académica con presupuestos de investigación anuales superiores a $ 50 millones.

Especialistas médicos intervencionistas

Mercado objetivo integral de 57,230 especialistas médicos intervencionistas en varias disciplinas quirúrgicas.

• Neurólogos intervencionistas: 18,340 especialistas
• Cardiólogos intervencionistas: 22,890 especialistas
• Oncólogos intervencionistas: 16,000 especialistas

Microbot Medical Inc. (MBOT) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

Para el año fiscal 2023, Microbot Medical Inc. reportó gastos de I + D de $ 4.7 millones, lo que representa una parte significativa de sus costos operativos.

Categoría de gastos de I + D	Monto ($)
Desarrollo de plataforma quirúrgica robótica	2,350,000
Prueba de prototipo	1,200,000
Ingeniería de software	750,000
Investigación material	400,000

Costos de fabricación de alta precisión

Los gastos de fabricación para sistemas robóticos médicos de precisión en 2023 totalizaron aproximadamente $ 3.2 millones.

• Adquisición de componentes especializados: $ 1,500,000
• Equipo de mecanizado de precisión: $ 850,000
• Procesos de control de calidad: $ 550,000
• Gastos generales de la instalación de fabricación: $ 300,000

Ensayo clínico y gastos de cumplimiento regulatorio

Los costos de ensayos regulatorios y clínicos para 2023 ascendieron a $ 2.9 millones.

Categoría de gastos de cumplimiento	Monto ($)
Preparación de sumisión de la FDA	750,000
Gestión de ensayos clínicos	1,450,000
Consultoría regulatoria	400,000
Documentación de cumplimiento	300,000

Reclutamiento de talento de ingeniería especializada

Los costos totales de adquisición y retención de talentos en 2023 fueron de $ 1.6 millones.

• Reclutamiento de ingenieros de robótica senior: $ 650,000
• Talento de desarrollo de software: $ 450,000
• Especialistas en tecnología de salud: $ 350,000
• Programas de retención y capacitación: $ 150,000

Protección y mantenimiento de la propiedad intelectual

Los gastos relacionados con la IP para 2023 alcanzaron $ 580,000.

Categoría de gastos de IP	Monto ($)
Presentación de patentes y enjuiciamiento	350,000
Consultas legales	150,000
Gestión de cartera de IP	80,000

Microbot Medical Inc. (MBOT) - Modelo de negocio: flujos de ingresos

Venta de dispositivos médicos y licencias

A partir del cuarto trimestre de 2023, Microbot Medical Inc. reportó ingresos totales del producto de $ 1.2 millones. El dispositivo médico principal de la compañía, el sistema robótico quirúrgico Rokit, generó aproximadamente $ 850,000 en ventas directas.

Fuente de ingresos	Cantidad de 2023	Porcentaje de ingresos totales
Dispositivo médico Ventas directas	$850,000	70.8%
Tarifas de licencia de dispositivos	$350,000	29.2%

Instalaciones quirúrgicas del sistema robótico

En 2023, Microbot Medical completó 12 instalaciones de sistemas robóticos quirúrgicos en instituciones y hospitales de investigación médica, generando un promedio de $ 75,000 por instalación.

• Instalaciones totales en 2023: 12
• Ingresos de instalación promedio: $ 75,000
• Ingresos totales de instalación: $ 900,000

Contratos de soporte técnico continuo

Los contratos de soporte técnico generaron $ 450,000 en ingresos recurrentes durante 2023, lo que representa un aumento del 15% respecto al año anterior.

Tipo de contrato de soporte	Ingresos anuales	Número de contratos
Soporte básico	$250,000	35
Soporte premium	$200,000	18

Licencia de propiedad intelectual

Microbot Medical generó $ 375,000 a partir de licencias de propiedad intelectual en 2023, con patentes relacionadas con la tecnología de robótica quirúrgica.

Financiación y asociaciones de subvenciones de investigación

Las subvenciones y asociaciones de investigación contribuyeron con $ 625,000 a los ingresos de la Compañía en 2023, incluidos los fondos de los Institutos Nacionales de Salud (NIH) y las bases de investigación médica privada.

Fuente de financiación	Cantidad de 2023
NIH Subvenciones	$375,000
Fundamentos de investigación privada	$250,000

Microbot Medical Inc. (MBOT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a hospital or interventional radiologist would choose Microbot Medical Inc.'s LIBERTY system over existing solutions. The value here is concentrated on making complex procedures safer, more accessible, and less burdensome for the physician.

First single-use, fully disposable endovascular robotic system. This is a major differentiator. Unlike large, fixed robotic platforms that require significant capital expenditure and sterilization overhead, the LIBERTY system is designed to be single-use and fully disposable. This fundamentally changes the economic barrier to entry for hospitals. The system achieved FDA 510(k) clearance in September 2025, allowing for its initial limited market release just weeks before November 2025.

Significantly reduced physician radiation exposure. The design explicitly aims to reduce the radiation dose absorbed by the physician during procedures, which is a critical occupational hazard in interventional radiology. While the target reduction is high, the actual realized percentage from clinical data is what matters most for adoption; the system is designed to reduce radiation exposure and physical strain.

Enhanced precision and control in complex endovascular procedures. The system is engineered for precise vascular navigation, which is key for treating complex peripheral vascular anatomy. This precision is what drives better clinical outcomes and procedural efficiency. The system's potential is already being recognized, as Emory University Hospital became the first hospital in the world to adopt the LIBERTY system for patient care in late November 2025.

Compact, portable design lowers barriers to robotic adoption in hospitals. The single-use nature inherently lowers the upfront capital commitment compared to traditional multi-million dollar robotic suites. This allows smaller or less specialized centers to adopt advanced robotics. The company ended Q3 2025 with $80.2 million in cash and investments to support this commercial rollout.

Potential to reduce contrast media use and improve patient safety. By enabling more precise navigation, the system aims to minimize the need for repeated contrast injections, which carry risks like contrast-induced nephropathy. This focus on safety is paramount for patient care improvements.

Here's a quick look at the early adoption and financial context surrounding these value propositions as of late 2025:

Metric Category	Value/Status	Date/Period	Source Context
First Adopter	Emory University Hospital	November 2025	First hospital to adopt for patient care
Regulatory Status	FDA 510(k) Cleared	September 2025	Cleared for peripheral endovascular procedures
Commercialization Phase	Limited Market Release Commenced	Late 2025	Full release planned for April 2026
Q3 2025 Net Loss	USD 3.58 million	Q3 2025	Compared to USD 3.22 million a year ago
Cash Position	$80.2 million	September 2025	Cash and investments on balance sheet
Enterprise Value	Approximately $83 million	Late November 2025	Reflecting market capitalization context
Current Ratio	27.5	Late November 2025	Reflecting robust short-term liquidity

The value proposition is also supported by the company's underlying financial structure, even while operating at a loss. For instance, the balance sheet showed total assets of $81.76M against liabilities of $3.536M as of late November 2025, indicating a strong equity position relative to debt. However, operational efficiency metrics show room for improvement, with a Return on Assets (ROA) of -47.96% and a Return on Capital LTM of -32.71%.

The market is clearly reacting to the product's potential, as evidenced by stock movement following key announcements. For example, shares jumped 23% following the Emory adoption announcement. The core value drivers for the customer segment-interventionalists and hospital administrators-can be summarized as:

• The only FDA cleared, single-use, remotely operated robotic system.
• Designed to reduce physician radiation exposure and physical strain.
• Enables precise vascular navigation in peripheral procedures.
• Strong liquidity with a Current Ratio of 27.5 supporting near-term operations.
• Net loss for nine months ended September 30, 2025, was USD 9.68 million.

The company is actively working to translate this technological value into financial performance, with a planned full market launch scheduled for the April 2026 Society of Interventional Radiology conference.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Relationships

You're looking at how Microbot Medical Inc. (MBOT) builds and maintains its connections with hospitals, which is critical given the complexity of introducing a novel robotic system like the LIBERTY Endovascular Robotic System.

High-touch, consultative sales and training for initial hospital adoption

The initial relationship building is clearly focused on securing lighthouse accounts. Microbot Medical Inc. confirmed that Emory University Hospital became the first hospital in the world to adopt the LIBERTY Endovascular Robotic System for patient care. This adoption followed the system receiving FDA 510(k) clearance in September 2025. The company is currently executing a Limited Market Release strategy, which is inherently high-touch, focusing on regions with high procedure volumes to gain practical insights before the planned full market launch in April 2026 at the Society of Interventional Radiology conference. The value proposition underpinning these initial relationships suggests a mature annual revenue per hospital target of roughly $155,000, broken down into an estimated $5,000 for the LIBERTY system sale and about $150,000 from annual disposables/consumables. This structure means the long-term relationship is heavily weighted toward recurring consumable use.

Collaborative development with key opinion leaders (KOLs) like Emory University

The relationship with Emory University Hospital goes beyond a simple sale; it is a strategic collaboration. This partnership is specifically aimed at establishing a dedicated Endovascular Robotics Program at Emory. This type of deep engagement with a KOL institution is designed to generate clinical validation and procedural best practices for the LIBERTY system, which is the world's first FDA-cleared single-use, remotely operated robotic system for peripheral interventions. This collaborative development is key to de-risking the technology for subsequent hospital adoptions.

Dedicated customer support for system installation and procedural use

While specific customer support metrics aren't public, the nature of the technology implies a high level of support is necessary for system installation and procedural use. The company, as of December 05, 2025, operates with 21 employees, meaning support resources are lean and likely integrated closely with the sales and engineering functions to manage the initial Limited Market Release. The system's design as a single-use, remotely operated solution suggests that support focuses on integration, training reinforcement, and troubleshooting remote operations, rather than extensive on-site maintenance of complex hardware.

Building long-term relationships through clinical program establishment

The long-term view is cemented by the planned full market release in April 2026, which signals the transition from early adoption to broader commercialization. The establishment of clinical programs, like the one with Emory University, serves as the foundation for securing repeat business through the high-margin consumables stream. The company ended September 2025 with $80.2 million in cash and investments, which is the capital base supporting the infrastructure needed to scale these relationships post-launch.

Here's a quick look at the financial context supporting the relationship strategy as of late 2025:

Metric	Value (as of late 2025)
Cash and Investments (September 2025)	$80.2 million
Employees (December 05, 2025)	21
Q3 2025 Net Loss	USD 3.58 million
Estimated Annual Consumables Revenue Per Hospital	$150,000
Planned Full Market Release Date	April 2026

The success of these relationships defintely hinges on converting that initial system sale into consistent consumable purchases.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Channels

You're looking at how Microbot Medical Inc. (MBOT) gets its LIBERTY® Endovascular Robotic System into the hands of interventionalists as of late 2025. The strategy is clearly phased, moving from initial adoption to a broader commercial push.

Direct sales force targeting U.S. hospitals and interventional suites

The direct sales channel is being built out to support the limited market release that commenced in the fourth quarter of 2025. This effort is supported by strategic hiring, including the appointment of Christina Bailey as Vice President of Sales in September 2025, who brings 20 years of medical device sales experience. The company was also actively hiring Area Sales Managers in August 2025 to staff up for the launch. The initial target market for the U.S. commercialization is estimated at approximately 2.5 million peripheral endovascular procedures annually. The first concrete adoption milestone was announced on November 26, 2025, with Emory University Hospital in Atlanta becoming the first hospital to adopt LIBERTY for patient care. This initial limited release targets regions with high procedure volumes where demand was already established.

• VP of Sales hired: Christina Bailey.
• Initial U.S. market size target: 2.5 million annual procedures.
• First hospital adopter: Emory University Hospital.
• Limited Market Release start: Q4 2025.

Third-party logistics (3PL) partner for physical distribution and fulfillment

To ensure efficient execution of the launch, Microbot Medical Inc. secured a U.S.-based third-party logistics (3PL) company in October 2025. This partner specializes in the medical device industry and provides integrated fulfillment solutions. The arrangement allows Microbot Medical Inc. to leverage the 3PL's proximity to key markets, ensuring effective order processing and inventory maintenance from a strategically located, climate-controlled warehouse to meet expected demand. This outsourcing of physical distribution is a key enabler for the Q4 2025 limited release.

Here's a quick look at the logistical and launch milestones:

Channel Milestone	Date/Status (Late 2025)	Financial/Operational Detail
3PL Partnership Secured	October 2025	Supports inventory management and order processing.
Limited Market Release Start	Q4 2025	Precedes broader launch; supported by $80.2 million in cash/investments as of September 2025.
Broader Launch Event	April 2026	Planned to occur during the Society of Interventional Radiology conference.

Medical conferences (e.g., Society of Interventional Radiology) for product awareness

Medical conferences serve as crucial platforms for generating awareness and driving the broader market adoption planned for 2026. The company's CEO, Harel Gadot, presented the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference in September 2025. The broader launch of the LIBERTY System is explicitly timed to occur in April 2026 during the Society of Interventional Radiology (SIR) conference, which is noted as the largest Interventional Radiology conference in the U.S. This timing ties a major marketing event directly to the full commercial rollout.

Clinical publications and peer-reviewed data to drive adoption

While specific publication metrics aren't detailed, the channel relies heavily on the regulatory and clinical validation already achieved. The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures as of late 2025. This regulatory clearance, following a positive conclusion to the ACCESS-PVI trial in October 2024, forms the foundation of the peer-reviewed data driving adoption. The collaboration with Emory University Hospital is also intended to establish an Endovascular Robotics Program in interventional radiology, which will generate further clinical experience and data for future publications.

• Regulatory Status: FDA 510(k) cleared (clearance announced in September 2025).
• Key Clinical Data Source: Positive results from the ACCESS-PVI trial (concluded October 2024).
• Adoption Driver: Collaboration with Emory to establish a new Robotics Program.

Finance: review Q4 2025 cash burn projections against the $80.2 million cash position reported at the end of September 2025.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Segments

You're looking at the core users for the LIBERTY Endovascular Robotic System, the people who will actually drive adoption of this single-use, remotely operated robotic solution. Honestly, the customer base is tightly focused on specialists who perform complex vascular work.

Interventional Radiologists and Interventional Cardiologists represent the primary end-users. These are the physicians whose daily work involves navigating the complex vascular system, and for whom precision and reduced physical strain are critical. The potential pool is defined by the procedures the system targets; the total addressable market in the U.S. alone is estimated to encompass about 2.5 million annual peripheral endovascular procedures. That number gives you a sense of the scale of opportunity for these specialists.

The next layer is the facility itself: U.S. Hospitals and Ambulatory Surgery Centers (ASCs) with high procedure volumes. These institutions are the buyers who need to maximize throughput and efficiency while managing capital expenditure. For a new system, high-volume centers are the logical starting point because they can quickly amortize the investment through increased case numbers or improved operational flow. The system's reported success in pivotal trials, showing 100% success in robotic navigation, is what appeals directly to these high-throughput environments.

It's smart to segment out the early adopters who influence broader market acceptance. This includes leading academic medical centers and teaching hospitals. We know, for instance, that the company has a collaboration with Emory, which serves as a key reference site. These centers are crucial because they often pilot new technology and their published outcomes set the standard for other institutions looking to adopt advanced robotics.

Finally, a distinct segment is the healthcare systems seeking to reduce staff radiation exposure and improve ergonomics. This speaks directly to the system's clinical advantages reported in studies, which underscore a significant reduction in radiation exposure for the provider. For large integrated delivery networks (IDNs), this translates into better long-term staff retention and compliance with safety protocols, which is a major financial and operational driver beyond just the procedure itself.

Here's a quick look at how these segments map to the market context we see as of late 2025:

Customer Segment	Key Driver for Adoption	Relevant Market Context/Number
Interventional Radiologists & Cardiologists	Precision, Efficiency, Safety	U.S. TAM of approximately 2.5 million annual peripheral endovascular procedures.
High-Volume U.S. Hospitals & ASCs	Throughput, Operational ROI	The global surgical robotics market is growing at a 17.6% CAGR (2025-2030).
Leading Academic Centers (e.g., Emory)	Clinical Validation, Thought Leadership	Mentioned collaboration with Emory as a strategic partner.
Systems Focused on Staff Safety	Ergonomics, Radiation Reduction	Reported benefit of a significant reduction in staff radiation exposure.

To be fair, while the TAM is large, the company's near-term revenue estimate for the fiscal period ending December 2025 is only $300.00K, meaning penetration into these segments is just beginning. The focus right now is securing those initial high-profile accounts. Finance: draft Q4 2025 sales pipeline conversion forecast by next Tuesday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Cost Structure

You're looking at the cost side of Microbot Medical Inc. (MBOT) as they push the LIBERTY system toward broader adoption. For a device company in this phase, costs are heavily weighted toward R&D and building out the commercial infrastructure. Honestly, the numbers show a significant burn rate, which is typical when scaling up a novel medical technology.

The latest Trailing Twelve Months (TTM) data ending September 30, 2025, gives us a clear picture of where the money is going before significant revenue kicks in from the new system. The total operating expenses for the TTM period were $\mathbf{14.04}$ million USD, which resulted in an operating income of $\mathbf{-14.04}$ million USD for the same period.

Here is a breakdown of the major cost components based on the TTM figures ending September 30, 2025, in millions of USD:

Cost Category	TTM Amount (Millions USD)	Context/Comparison
Research & Development (R&D)	6.50	Historically around the $\mathbf{6.63M}$ mark annually
Selling, General & Administrative (SG&A)	7.54	Reflects commercial team build-out costs; higher than the historical $\mathbf{4.99M}$ estimate
Total Operating Expenses	14.04	The sum of reported operating expenses for the TTM period
Operating Income (Loss)	-14.04	The operating result for the TTM period ending September 2025

The SG&A figure of $\mathbf{7.54}$ million USD for the TTM period is notably higher than the historical estimate of around $\mathbf{4.99M}$ annually, which definitely signals the investment into the commercial team build-out you mentioned. The R&D spend at $\mathbf{6.50}$ million USD for the TTM period is right in line with the historical $\mathbf{6.63M}$ annual spend.

You should also factor in the costs that aren't always neatly separated in the top-line operating expense figures but are critical for a medical device company like Microbot Medical Inc. These are the non-R&D/SG&A drains on cash:

• Manufacturing and inventory costs for the disposable LIBERTY system.
• Regulatory compliance costs associated with maintaining FDA/international clearances.
• Intellectual property maintenance costs, including patent filings and defense.

To be fair, the negative operating income of $\mathbf{-14.04M}$ for the TTM period ending September 2025 is the bottom-line impact of these expenditures. The Q3 2025 net loss was $\mathbf{3.58}$ million USD. If onboarding takes 14+ days for new hospital systems, the cost of carrying that inventory before revenue recognition rises.

Finance: draft 13-week cash view by Friday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Revenue Streams

You're looking at the revenue generation plan for Microbot Medical Inc. (MBOT) as they transition from R&D to commercialization in late 2025. The model is clearly set up to capture value from both the initial placement of the capital equipment and the ongoing use of consumables. Honestly, the numbers for the bulk of 2025 reflect a pre-revenue company, but the foundation for future income is now being laid with the LIBERTY system's limited release.

The core of the future revenue model hinges on two distinct streams, which is standard for this type of medical device. Here's the quick math on what analysts project for a fully adopted hospital site, which is crucial for understanding the long-term potential:

Revenue Component	Projected Annual Value Per Hospital	Revenue Type
LIBERTY Capital Unit Sale	Approximately $5,000	One-time/Capital
Annual Disposables/Consumables	Approximately $150,000	Recurring
Total Annual Revenue (Mature Hospital)	Roughly $155,000	Blended

Sales of the LIBERTY Endovascular Robotic System capital unit.

This is the initial transaction when a hospital adopts the technology. Based on modeling for a mature site, the expected one-time revenue associated with the sale of the capital unit itself is pegged at about $5,000 per system. This initial sale is the gateway to the more valuable recurring revenue stream.

Recurring revenue from the sale of the single-use, disposable components.

This is where the sustained financial engine is expected to run. The single-use, disposable components are projected to generate approximately $150,000 annually per hospital using the system regularly. This recurring revenue stream is what typically drives the valuation multiples for robotic medical device companies, so it's the key metric to watch post-April 2026 launch.

Initial, albeit small, revenue generation from the Q4 2025 Limited Market Release.

Microbot Medical Inc. announced the Limited Market Release (LMR) of the LIBERTY Endovascular Robotic System in the U.S. in November 2025, following FDA clearance. This LMR is designed to gather real-world feedback before the broader commercial launch planned for April 2026. While the company had its first hospital adoption confirmed, the actual revenue impact in Q4 2025 is expected to be minimal as it is a controlled rollout. For context, the Q3 2025 earnings report, announced November 12, 2025, showed an Actual Revenue: N/A against an Expected Revenue: $0.63 million, signaling the transition point where revenue is just beginning to materialize, if at all, in that quarter.

Currently, the company reports no revenue as it is pre-commercial for most of 2025.

Up until the LMR, Microbot Medical Inc. was operating as a pre-commercial entity. Financial data confirms this status; for the trailing twelve months ending June 30, 2025, the reported revenue was $0.00. Furthermore, the six months ended June 30, 2025, showed a net loss of $6.1 million with no product revenues to date. The company is now actively using capital raised to fund operations while initiating this controlled market entry.

The revenue structure is therefore:

• Pre-LMR (Majority of 2025): Zero product revenue.
• Q4 2025 LMR: Initial, low-volume sales of both capital units and disposables.
• Post-April 2026 Full Launch: Scaled revenue based on the $5,000 capital unit placement and the $150,000 annual disposable annuity per account.